Effect of rosiglitazone on plasma adiponectin levels and arterial stiffness in subjects with prediabetes or non-diabetic metabolic syndrome.
OBJECTIVE
Thiazolidinediones have favorable influences on surrogate markers of atherosclerosis such as adiponectin, and arterial stiffness in diabetic patients. However, it is not well known whether these beneficial effects occur in subjects without diabetes, such as prediabetes or the non-diabetic metabolic syndrome (MetS). The present study was therefore designed to evaluate the effectiveness of the insulin-sensitizing agent rosiglitazone on circulating adipocytokine levels and brachial-ankle pulse wave velocity (baPWV) in non-diabetics.


METHODS
Ninety-nine subjects with prediabetes or non-diabetic MetS were randomly assigned to either rosiglitazone or an untreated control group (50 and 49 subjects respectively). The rosiglitazone group was treated daily for 12 weeks with 4 mg rosiglitazone. All subjects received a 75 g oral glucose test (OGTT) before and after treatment. In addition, baPWV, together with the levels of adiponectin, resistin, and high sensitivity C-reactive protein (hsCRP) were determined.


RESULTS
Rosiglitazone treatment significantly increased circulating adiponectin levels (P < 0.001) relative to the control group (P = 0.21). Plasma resistin levels were unchanged in both the rosiglitazone-treated and -untreated groups, but baPWV and hsCRP were significantly decreased (P < 0.001 and P = 0.003 respectively) in the rosiglitazone group only. Multiple linear regression analysis showed that changes in plasma adiponectin and baPWV were significantly affected by rosiglitazone treatment.


CONCLUSIONS
These data suggest that rosiglitazone may have an anti-atherogenic effect in subjects with prediabetes or non-diabetic MetS.
Division of Endocrinology and Metabolism, Department of Internal Medicine, Anam Hospital, Korea University Medical Center, Seoul.
Sin Gon
SG
Kim
Ohk Hyun
OH
Ryu
Hee Young
HY
Kim
Kye Won
KW
Lee
Ji A
JA
Seo
Nan Hee
NH
Kim
Kyung Mook
KM
Choi
Juneyoung
J
Lee
Sei Hyun
SH
Baik
Dong Seop
DS
Choi
D052242:Adiponectin / Q000097:blood*; D000328:Adult; D000368:Aged; D000886:Anthropometry; D001158:Arteries / Q000187:drug effects* / Q000503:physiopathology*; D001916:Brachial Artery / Q000503:physiopathology; D002097:C-Reactive Protein / Q000378:metabolism; D016207:Cytokines / Q000097:blood; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D008297:Male; D024821:Metabolic Syndrome / Q000503:physiopathology*; D008875:Middle Aged; D011236:Prediabetic State / Q000503:physiopathology*; D052243:Resistin / Q000097:blood; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology*
D052242:Adiponectin; D016207:Cytokines; D007004:Hypoglycemic Agents; D052243:Resistin; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D002097:C-Reactive Protein